Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer

Pancreas

Volumn 26, Issue 1, 2003, Pages 56-64

  Büchler, Peter ^a   Reber, Howard A ^a   Büchler, Manuela ^a   Shrinkante, Shailesh ^b   Büchler, Markus W ^b   Friess, Helmut ^b   Semenza, Gregg L ^c   Hines, Oscar J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ARTICLE; CANCER CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEOVASCULARIZATION (PATHOLOGY); NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; CELL HYPOXIA; CELL NUCLEUS; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037215306     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200301000-00010     Document Type: Article

References (53)

1. Parker SL, Davis KJ, Wingo PA, et al. Cancer statistics by race and ethnicity. CA Cancer J Clin 1998;48:31-48.
2. Gudjonsson B. Cancer of the pancreas. 50 Years of surgery. Cancer 1987;60: 2284-303.
3. Friess H, Uhl W, Büchler MW. Surgical treatment of pancreatic cancer. Dig Surg 1994;11:378-86.
4. Warshaw AL, Fernandez-Del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
5. Patel AG, Toyama MT, Alvarez C, et al. Pancreatic interstitial pH in human and feline chronic pancreatitis. Gastroenterology 1995;109:1639-45.
6. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
7. Moulder JE, Rockwell S. Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313-41.
8. Durand RE, LePard NE. Modulation of tumor hypoxia by conventional chemotherapeutic agents. Int J Radiat Oncol Biol Phys 1994;29:481-6.
9. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379:88-91.
10. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
11. Laderoute KR, Mendonca HL, Calaoagan JM, et al. Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments: A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. J Biol Chem 1999;274:12890-7.
12. Büchler P, Hines OJ, Büchler M, et al. Tumor hypoxia in vivo predicts metastatic tumor growth and regulates the angiogenic cytokine VEGF in pancreatic cancer. Gastroenterology 2000;118:A765.
13. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-54.
14. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993;90:4304-8.
15. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helixloop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
16. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
17. Semenza GL. Hypoxia-inducible factor 1: Master regulator of O2 homeostasis. Curr Opin Genet Dev 1998;5:588-9.
18. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-78.
19. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Amt) as a component of the DNA binding form of the Ah receptor. Science 1992;256:1193-5.
20. Hoffman EC, Reyes H, Chu FF, et al. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991;252:954-8.
21. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. Blood 1993;82:3610-5.
22. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16: 4604-13.
23. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997;94:8104-9.
24. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 1998;394:485-90.
25. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998;12:149-62.
26. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15.
27. Plate KH, Breier G, Welch HA, et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1993;359:845-8.
28. Yuan F, Chen Y, Deilian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70.
29. Kuroda M, Oka T, Oka Y, et al. Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J Clin Endocrinol Metab 1995;80:3196-200.
30. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309-16.
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
32. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
33. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59:5830-5.
34. di Mola FF, Friess H, Scheuren A, et al. Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 1999;229:67-75.
35. Murakami Y, Sekiya T. Accumulation of genetic alterations and their significance in each primary human cancer and cell line. Mutat Res 1998;400:421-37.
36. Seufferlein T, Van Lint J, Liptay S, et al. Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 1999;116:1441-52.
37. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: Sensitive to asparaginase. Int J Cancer 1977;19:128-35.
38. Fanjul M, Hollande E. Morphogenesis of "duct-like" structures in three-dimensional cultures of human cancerous pancreatic duct cells (Capan-1). In Vitro Cell Dev Biol Anim 1993;29A:574-84.
39. Lieber M, Mazzetta J, Nelson-Rees W, et al. Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975;15:741-7.
40. Wang GL, Jiang BH, Semenza GL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem Biophys Res Commun 1995;216:669-75.
41. Durand RE, Sham E. The lifetime of hypoxic human tumor cells. Int J Radiat Oncol Biol Phys 1998;42:711-5.
42. Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 1998;58:3547-50.
43. Robinson MF, Dupuis NP, Kusumoto T, et al. Increased tumor oxygenation and radiation sensitivity in two rat tumors by a hemoglobin-based, oxygen-carrying preparation. Artif Cells Blood Substit Immobil Biotechnol 1995;23:431-8.
44. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13: 139-68.
45. Teicher BA, Holden SA, Ara G, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. Int J Cancer 1995;61:732-7.
46. van Zijl PC, Eleff SM, Ulatowski JA, et al. Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging [see comments]. Nat Med 1998;4:159-67.
47. Holz H, Hines OJ, Büchler P, et al. Hypoxia increases the malignant potential of pancreatic cancer. Gastroenterology 1999;116:A1320.
48. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
49. Boros LG, Torday ST, Lim S, et al. Transforming growth factor β2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. Cancer Res 2000;60:1183-5.
50. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
51. Zhong H, Agani F, Baccala AA, et al. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res 1998;58:5280-4.
52. Mukhopadhyay D, Tsiokas L, Zhou XM, et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995;375:577-81.
53. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997;3:515-20.